Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
TACE possibly plays a significant role in contributing to a subgroup of surviving residual
tumor tissue which is characterized by more aggressive biology. This explains the strong
scientific rationale for exploring the role of anti-angiogenic therapy such as sorafenib to
remedy and strengthen the therapeutic efficacy of TACE to combat liver cancers. Sorafenib
plays a prominent auxiliary role by further suppressing the tumor growth and prolonging the
time to recurrence and progression. Performing TACE under sorafenib administration may have
synergic effect on hepatic tumoral lesions.